VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
SDGR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
SDGRSchrödinger, Inc.
$17.00$1.3B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

SDGR logoSchrödinger, Inc.(SDGR)Earnings, Financials & Key Ratios

SDGR•NASDAQ
$17.00
Price updated Jul 6, 2026
SectorHealthcareIndustryHealthcare ITSub-IndustryLife Sciences and Precision Medicine Software
AboutSchrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Show more
  • Revenue$256M+23.3%
  • EBITDA-$161M+20.8%
  • Net Income-$103M+44.8%
  • EPS (Diluted)-1.41+45.1%
  • Gross Margin55.74%-12.4%
  • EBITDA Margin-62.87%+35.8%
  • Operating Margin-65.23%+35.3%
  • Net Margin-40.36%+55.2%
  • ROE-26.29%+31.9%

SDGR Price & Volume

Schrödinger, Inc. (SDGR) stock price & volume — 10-year historical chart

Loading chart...

Persistent R&D Intensity Masks Clinical Pipeline Volatility

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Clinical Pipeline Execution Risk

Key Thesis Takeaways

  • Schrödinger's dual-model approach of software licensing and internal drug discovery creates significant revenue lumpiness, as evidenced by the 1.6% revenue contraction in 2026Q1.
  • While the company maintains a conservative capital structure with a 0.34 debt-to-equity ratio, the persistent R&D spend exceeding $40 million per quarter continues to weigh heavily on operating profitability.
  • Investors should monitor the company's ability to achieve consistent milestone payments, as the current net loss of $60.0 million in 2026Q1 highlights the substantial execution risk inherent in its clinical-stage pipeline.

Verdict Logic

the company's inability to achieve operating leverage, evidenced by a -83.3% operating margin in 2026Q1, suggests that the high cash burn rate remains a primary concern for long-term sustainability.

SDGR Growth Metrics

Schrödinger, Inc. (SDGR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years18.81%
3 Years12.24%
TTM10.59%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM46.16%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM46.39%

Return on Capital

10 Years-30.22%
5 Years-25.88%
3 Years-29.72%
Last Year-28.57%

SDGR Recent Earnings

Schrödinger, Inc. (SDGR) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 5, 2026
Metric
Actual
Est
EPS
$0.81-44.6%
$0.56
Rev
$59M+23.2%
$48M
Q1 2026
Feb 25, 2026
Metric
Actual
Est
EPS
$0.44+438.5%
$0.13
Rev
$87M+4.1%
$84M
Q4 2025
Nov 5, 2025
Metric
Actual
Est
EPS
$0.45+40.0%
$0.75
Rev
$54M-35.0%
$84M
Q3 2025
Aug 6, 2025
Metric
Actual
Est
EPS
$0.59+28.9%
$0.83
Rev
$55M+8.8%
$50M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 5, 2026
$0.81vs $0.56-44.6%
$59Mvs $48M+23.2%
Q1 2026Feb 25, 2026
$0.44vs $0.13+438.5%
$87Mvs $84M+4.1%
Q4 2025Nov 5, 2025
$0.45vs $0.75+40.0%
$54Mvs $84M-35.0%
Q3 2025Aug 6, 2025
$0.59vs $0.83+28.9%
$55Mvs $50M+8.8%
Based on last 12 quarters of dataView full earnings history →

Latest SDGR News

Recent stock market news and headlines for Schrödinger, Inc. (SDGR)

GuruFocus·Jun 18, 2026
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger, Inc. (Nasdaq: SDGR) today reported that on June 12, 2026, the company granted restricted stock units (RSUs) with respect to 10,771 shares of the

Business Wire·Jun 18, 2026
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on June 12, 2026, the company granted restricted stock units (RSUs) with respect to 10,771 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement.

Peers Comparison

Key metrics vs top competitors for Schrödinger, Inc. (SDGR)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
SDGR logoSDGRSchrödinger, Inc.Current
$17.00$1.27B-12.0623.29%-40.36%-26.29%—
RXRX logoRXRXRecursion Pharmaceuticals, Inc.
$3.96$1.77B-2.7526.92%-844.46%-54.32%—
ABSI logoABSIAbsci Corporation
$11.54$1.8B-13.74-38.24%-6450.76%-63.58%—
RLAY logoRLAYRelay Therapeutics, Inc.
$18.90$3.58B-11.7453.44%-2554.14%-43.94%—
CDNS logoCDNSCadence Design Systems, Inc.
$375.77$103.64B92.5514.12%21.18%21.06%—
CERT logoCERTCertara, Inc.
$7.13$1.11B-713.008.75%-3.6%-1.43%—

Compare SDGR vs Peers

Schrödinger, Inc. (SDGR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RXRX

Most directly comparable listed peer for SDGR.

Scale Benchmark

vs NVDA

Larger-name benchmark to compare SDGR against a more recognizable public peer.

Peer Set

Compare Top 5

vs RXRX, ABSI, RLAY, CDNS

SDGR SEC Filings & Documents

Schrödinger, Inc. (SDGR) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 5, 2026·SEC

Material company update

Mar 12, 2026·SEC

Material company update

Feb 25, 2026·SEC

10-K Annual Reports

4
FY 2026

Feb 25, 2026·SEC

FY 2025

Feb 26, 2025·SEC

FY 2024

Feb 28, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 5, 2026·SEC

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 6, 2025·SEC

Get notified when SDGR posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

SDGR Frequently Asked Questions

Schrödinger, Inc. (SDGR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Schrödinger, Inc.'s revenue?

Schrödinger, Inc. (SDGR) reported $254.9M in revenue for fiscal year 2025. This represents a 358% increase from $55.7M in 2017.

How fast is Schrödinger, Inc. growing?

Schrödinger, Inc. (SDGR) grew revenue by 23.3% over the past year. This is strong growth.

Is SDGR profitable?

Schrödinger, Inc. (SDGR) reported a net loss of $103.5M for fiscal year 2025.

Dividend & Returns
What is SDGR's return on equity?

Schrödinger, Inc. (SDGR) has a return on equity (ROE) of -26.3%. Negative ROE indicates the company is unprofitable.

What is Schrödinger, Inc.'s free cash flow?

Schrödinger, Inc. (SDGR) had negative free cash flow of $148.4M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in SDGR back in 2017?

Total return calculator · dividends reinvested · 9+ years of data

See returns →